Table 1.
Characteristic | Case 1 | Case 2 | Case 3 | Case 4 | Case 5 |
---|---|---|---|---|---|
Age, y | 44 | 55 | 47 | 40 | 70 |
Gender | Female | Female | Male | Male | Male |
DKA severity | Mild | Severe | Moderate | Mild | Moderate |
Comorbidities | T2DM, RA/SLE overlap, Hypertension | None | None | T1DM, Hypertension | T2DM, Obesity, IHD, Dyslipidemia |
Home medications | Metformin, Gliclazide, Prednisolone, Etanercept, Methotrexate, Hydroxychloroquine | None | None | Insulin Lantus*, Insulin Mixtard†, enalapril | Insulin |
Length of stay, d | 16 | 11 | 12 | 21 | 30 |
In-hospital steroids | Yes | No | No | Yes | No |
Mortality | No | No | No | No | Yes |
DKA = diabetic ketoacidosis; IHD = Ischaemic Heart disease; RA = rheumatoid arthritis; SLE = systemic lupus erythematosus; T1DM = type 1 diabetes; T2DM = type 2 diabetes.
Sanofi-Aventis, Bridgewater Township, New Jersey.
Eli Lilly and Company, Indianapolis, Indiana.